Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
CDX-1140 is an antibody that binds CD40 and activates signaling, potentially resulting in enhanced anti-tumor immune response (Blood, 128(22), 1848).
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|CDX-1140||CDX 1140|CDX1140||CD40 Antibody 12||CDX-1140 is an antibody that binds CD40 and activates signaling, potentially resulting in enhanced anti-tumor immune response (Blood, 128(22), 1848, PMID: 30382327).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||Advanced Solid Tumor||not applicable||CDX-1140||Phase I||Emerging||In a Phase I trial, CDX-1140 demonstrated safety and expected lymphocyte activation and cytokine responses in patients with advanced solid tumors (AACR Annual Meeting 2019, Abstract LB_194; NCT03329950).||detail...|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|
|NCT03329950||Phase I||CDX-1140 + CDX-301 CDX-1140||A Study of CDX-1140 as Monotherapy or in Combination in Patients With Advanced Solid Tumors||Recruiting||USA||0|
|NCT04536077||Phase II||CDX-1140 + CDX-301 CDX-1140||Immunologic Effects of CDX-301 and CDX-1140 in Resectable Pancreatic Cancer Patients||Recruiting||USA||0|